Grant: Foundation Grant
University of British Columbia
$2,023,101.00
Molecular and cellular biology of T regulatory cells
EF 2016-17
Résumé
The goal of my research is to understand how our immune system regulates itself and to use this information to develop new ways to treat patients with immune-related diseases, such as autoimmunity or transplant rejection. A healthy immune system must strike a balance between attacking infectious or dangerous substances while not reacting to our own cells and tissues. This delicate balancing act is called immune tolerance. Both autoimmune diseases and transplant complications are caused by disrupted immune tolerance. At present, immunosuppressive drugs are our only treatment for these conditions. Yet these drugs suppress all immune responses, putting patients at risk of infection and cancer, often without controlling their disease. We need to find better ways to prevent harmful immune responses.
I am an expert is the study of a type of white blood cell called T regulatory cells, or Tregs, which coordinate immune responses and maintain immune tolerance. My work has defined how Tregs develop and function, and led to clinical trials to test use of Tregs as a cell therapy in transplantation and autoimmunity. I developed methods to monitor the presence of Tregs in blood and tissues, allowing more precise measurement of immune tolerance.
If used as a treatment, Tregs could control pathological immune responses without altering healthy immune balance. Towards this aim, the next stage of my research has 3 goals, to:
1) create "designer" Tregs that are engineered to be active only in the presence of a transplant and test their ability to prevent transplant rejection and preserve normal immunity;
2) design new ways to alter Tregs so their function is tailored to specific disease contexts; and
3) identify biological pathways that regulate Tregs, so that they can be targeted for new treatment options.
My research will enable new Treg-based therapies to prevent and treat the many chronic diseases that are caused by a failure of immune tolerance.
Programme
Foundation Grant
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
354040
Name
Levings Megan K
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Foundation Grant
Projecttitle
Molecular and cellular biology of T regulatory cells
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$2,023,101
Cihrequipment2
$0
Programname2
Foundation Grant
Keyworddelim
Autoimmunity; Cell Therapy; Chemokines; Cytokines; Immune Regulation; T Cells; T Regulatory Cells; Transplantation
Abstract
The goal of my research is to understand how our immune system regulates itself and to use this information to develop new ways to treat patients with immune-related diseases, such as autoimmunity or transplant rejection. A healthy immune system must strike a balance between attacking infectious or dangerous substances while not reacting to our own cells and tissues. This delicate balancing act is called immune tolerance. Both autoimmune diseases and transplant complications are caused by disrupted immune tolerance. At present, immunosuppressive drugs are our only treatment for these conditions. Yet these drugs suppress all immune responses, putting patients at risk of infection and cancer, often without controlling their disease. We need to find better ways to prevent harmful immune responses.
I am an expert is the study of a type of white blood cell called T regulatory cells, or Tregs, which coordinate immune responses and maintain immune tolerance. My work has defined how Tregs develop and function, and led to clinical trials to test use of Tregs as a cell therapy in transplantation and autoimmunity. I developed methods to monitor the presence of Tregs in blood and tissues, allowing more precise measurement of immune tolerance.
If used as a treatment, Tregs could control pathological immune responses without altering healthy immune balance. Towards this aim, the next stage of my research has 3 goals, to:
1) create "designer" Tregs that are engineered to be active only in the presence of a transplant and test their ability to prevent transplant rejection and preserve normal immunity;
2) design new ways to alter Tregs so their function is tailored to specific disease contexts; and
3) identify biological pathways that regulate Tregs, so that they can be targeted for new treatment options.
My research will enable new Treg-based therapies to prevent and treat the many chronic diseases that are caused by a failure of immune tolerance.
Competitiondate
201610
Approvedterm2
7 yrs 0 mth
Pinamesdelim
Levings, Megan K
Approvedterm
7 ans 0 mois
Cihrcontribution2
~ $2,023,101~ $0~